EFFICACY AND SAFETY OF BEMPEDOIC ACID IN LIPID DISORDER THERAPY: A REVIEW OF CLINICAL TRIALS

被引:0
作者
Dabrowska, Paulina [1 ]
Zuber, Michal [2 ]
Dacka, Michal [3 ]
机构
[1] Stefan Cardinal Wyszynski Prov Specialist Hosp Lub, Al Krasnicka 100, PL-20718 Lublin, Poland
[2] Independent Publ Clin Hosp 4 Lublin, Ul Kazimierza Jaczewskiego 8, PL-20954 Lublin, Poland
[3] 1 Mil Clin Hosp Lublin, Al Raclawickie 23, PL-20049 Lublin, Poland
来源
PROSPECTS IN PHARMACEUTICAL SCIENCES | 2024年 / 22卷 / 03期
关键词
KEYWORDS: bempedoic acid; nonstatin therapy; statin intolerance; atherosclerotic cardiovascular disease; ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE; LOWERING THERAPIES; CHOLESTEROL; STATINS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
LDL level is a key risk factor for atherosclerotic cardiovascular disease. Bempedoic acid is an innovative hypolipemic drug, particularly useful for patients with statin intolerance. The article focuses on analyzing the results of clinical trials on the mechanisms of action, efficacy and safety of bempedoic acid used both as monotherapy and in combination with other hypolipemic drugs. Scientific evidence based on the CLEAR: Tranquility, Harmony, Serenity, Wisdom, Outcomes study, among others, is presented. Its significant effects on lowering LDL-C, non-HDL-C, and hsCRP levels are highlighted, with important implications for the prevention and treatment of cardiovascular disease. It also outlines how bempedoic acid is included in current Polish guidelines for the treatment of lipid disorders. The paper also points to new areas of research, including potential applications of bempedoic acid in specific patient groups, such as pregnant women. In addition, the article addresses issues related to the longterm use and safety of bempedoic acid, particularly in the context of reducing cardiovascular risk and lowering blood lipid levels, which is crucial for patients with statin intolerance.
引用
收藏
页码:120 / 126
页数:7
相关论文
共 46 条
  • [1] [Anonymous], Bempedoic acid
  • [2] Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid
    Ballantyne, Christie M.
    Bays, Harold E.
    Louie, Michael J.
    Smart, Jeremy
    Zhang, Yang
    Ray, Kausik K.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (15):
  • [3] Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study)
    Ballantyne, Christie M.
    Banach, Maciej
    Bays, Harold E.
    Catapano, Alberico L.
    Laufs, Ulrich
    Stroes, Erik S. G.
    Robinson, Paula
    Lei, Lei
    Ray, Kausik K.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2022, 174 : 1 - 11
  • [4] Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
    Ballantyne, Christie M.
    Laufs, Ulrich
    Ray, Kausik K.
    Leiter, Lawrence A.
    Bays, Harold E.
    Goldberg, Anne C.
    Stroes, Erik S. G.
    MacDougall, Diane
    Zhao, Xin
    Catapano, Alberico L.
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (06) : 593 - 603
  • [5] Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
    Ballantyne, Christie M.
    Banach, Maciej
    Mancini, G. B. John
    Lepor, Norman E.
    Hanselman, Jeffrey C.
    Zhao, Xin
    Leiter, Lawrence A.
    [J]. ATHEROSCLEROSIS, 2018, 277 : 195 - 203
  • [6] PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
    Banach, Maciej
    Burchardt, Pawl
    Chlebus, Krzysztof
    Dobrowolski, Piotr
    Dudek, Dariusz
    Dyrbus, Krzysztof
    Gasior, Mariusz
    Jankowski, Piotr
    Jozwiak, Jacek
    Klosiewicz-Latoszek, Longina
    Kowalska, Irina
    Malecki, Maciej
    Prejbisz, Aleksander
    Rakowski, Michat
    Rysz, Jacek
    Solnica, Bogdan
    Sitkiewicz, Dariusz
    Sygitowicz, Grazyna
    Sypniewska, Grazyna
    Tomasik, Tomasz
    Windak, Adam
    Zozulinska-Ziolkiewicz, Dorota
    Cybulska, Barbara
    [J]. ARCHIVES OF MEDICAL SCIENCE, 2021, 17 (06) : 1447 - 1547
  • [7] Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
    Bilen, Ozlem
    Ballantyne, Christie M.
    [J]. CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (10)
  • [8] ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia
    Burke, Amy C.
    Huff, Murray W.
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2017, 28 (02) : 193 - 200
  • [9] Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia
    Cicero, Arrigo F. G.
    Fogacci, Federica
    Cincione, Ivan
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (09) : 1031 - 1037
  • [10] Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis
    Cicero, Arrigo F. G.
    Fogacci, Federica
    Hernandez, Adrian V.
    Banach, Maciej
    [J]. PLOS MEDICINE, 2020, 17 (07)